Table 2.
Indication, mean hemoglobin value and need of transfusional support in all patients, and between premenopausal and menopausal groups n (%)
| No. of patients (n = 183) | All | PMW (30.6%, n = 56) | MW (69.4%, n = 127) | P value1 |
| Indication for CE | 0.11 | |||
| Occult OGIB | 151 (82.5) | 50 (89.3) | 101 (79.5) | |
| Overt OGIB | 32 (17.5) | 6 (10.7) | 26 (20.5) | |
| IDA | 149 (81.4) | 50 (89.3) | 99 (78.0) | |
| Positive fecal occult blood test | 2 (1.1) | 0 (0) | 2 (1.6) | |
| Hematochezia | 14 (7.7) | 2 (3.6) | 12 (9.4) | |
| Melena | 18 (9.8) | 4 (7.1) | 14 (11.0) | |
| Hb prior to CE, g/dL | 9.7 ( ± 2.0) | 10.4 ( ± 1.7) | 9.3 ( ± 2.1) | 0.001 |
| Need of transfusional support prior to CE | 63 (34.4) | 7 (12.5) | 56 (44.1) | < 0.001 |
1
t-test: χ2 test, as appropriate; P value of 0.05 indicating statistical significance. CE: Capsule endoscopy; PMW: Premenopausal women; MW: Menopausal women; OGIB: Obscure gastrointestinal bleeding; IDA: Iron deficiency anemia; Hb: Hemoglobin.